ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Financial Statements and Exhibits
Item 9.01.
|
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit Number |
|
Description |
|
|
|
|
| 10.1# |
Award/Contract between the Registrant and the U.S. Army Medical Research and Materiel Command, dated May 11, 2015. |
|
| 10.2 |
Modification of Contract W81XWH-15-C-0046 between the Registrant and the U.S. Army Medical Research and Materiel Command, effective March 9, 2017. |
|
|
# |
Material in the exhibit marked with a [*] has been omitted Omitted portions have been filed separately with the SEC. |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date: March 10, 2017 |
ACELRX PHARMACEUTICALS, INC.
|
|
|
|
|
By: |
/s/ Jane Wright-Mitchell |
|
|
|
|
Jane Wright-Mitchell |
|
|
|
|
Chief Legal Officer |
|
EXHIBIT INDEX
|
Exhibit Number |
|
Description |
|
|
|
|
| 10.1# |
Award/Contract between the Registrant and the U.S. Army Medical Research and Materiel Command, dated May 11, 2015. |
|
| 10.2 |
Modification of Contract W81XWH-15-C-0046 between the Registrant and the U.S. Army Medical Research and Materiel Command, effective March 9, 2017. |
|
|
# |
Material in the exhibit marked with a [*] has been omitted |
About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer. ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Recent Trading Information
ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) closed its last trading session up +0.05 at 3.15 with 179,353 shares trading hands.